Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer.
Yung-Sung YehMing-Yii HuangCheng-Jen MaChing-Wen HuangHsiang-Lin TsaiYen-Cheng ChenChing-Chun LiFang-Jung YuHsiang-Yao ShihJaw-Yuan WangPublished in: Journal of oncology (2020)
Neoadjuvant CCRT achieved more favorable OS and PFS than did neoadjuvant chemotherapy alone, without significant increases of toxicity in patients. However, prospective randomized trials comparing treatment modalities are necessary to confirm the potential advantages of neoadjuvant CCRT.
Keyphrases
- locally advanced
- neoadjuvant chemotherapy
- rectal cancer
- squamous cell carcinoma
- phase ii study
- radiation therapy
- end stage renal disease
- sentinel lymph node
- ejection fraction
- newly diagnosed
- small cell lung cancer
- chronic kidney disease
- oxidative stress
- peritoneal dialysis
- prognostic factors
- lymph node
- risk assessment
- clinical trial
- combination therapy
- patient reported
- replacement therapy
- study protocol